NASDAQ · FBLG
Healthcare · Biotechnology
$1.35
Up+$0.09 (+6.48%)
Updated Aug 25, 2026, 2:17 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
FBLG does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning FBLG.
FBLG research
Company profile and research snapshot.
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | Maxim Group | Hold | — |
| Apr 16, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 26, 2026 | D. Boral Capital | Hold | — |
| Mar 12, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 18, 2026
FibroBiologics reports promising preclinical results for a novel joint repair therapy, offering a faster, scalable alternative to surgery.
Benzinga · Aug 18, 2026
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic
Benzinga · Aug 11, 2026
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation proceduresHOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a
Benzinga · Aug 5, 2026
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FBLG.
